Gold prices steady ahead of Fed decision, Trump’s tariff deadline
Protagonist Therapeutics (NASDAQ:PTGX) President and CEO Dinesh V. Patel, Ph.D., sold 10,415 shares of common stock on July 25, 2025, at prices ranging from $54.75 to $54.82, for a total value of $570,533. The sale comes as the $3.48 billion biotech company trades near its 52-week high, having gained 48% over the past six months.
Following the transaction, Patel directly owns 520,603 shares of Protagonist Therapeutics. The sale was disclosed in a Form 4 filing with the Securities and Exchange Commission. With the company’s Q2 earnings report due on July 31, InvestingPro subscribers can access detailed insider trading patterns and 17 additional investment tips to make informed decisions.
In other recent news, Protagonist Therapeutics has garnered significant attention from multiple analyst firms due to developments in its drug candidates. H.C. Wainwright reaffirmed its Buy rating with an $80.00 price target after presenting full 32-week results from the Phase 3 VERIFY study of rusfertide at ASCO 2025. This data has strengthened confidence in rusfertide’s potential to become a standard treatment for polycythemia vera (PV). Meanwhile, Citi initiated coverage with a Buy rating and a $72.00 price target, citing the promising potential of Protagonist’s drug candidates, including rusfertide and icotrokinra, in collaboration with major pharmaceutical companies. BTIG also maintained its Buy rating and set an $82.00 price target, following additional data presented at ASCO 2025 that confirmed rusfertide’s efficacy in treating PV. Clear Street, however, adjusted its price target for Protagonist Therapeutics to $62 from $65 while maintaining a Buy rating, reflecting a reassessment of the company’s strategy after recent management updates. Despite the varied price targets, the consistent Buy ratings underscore the optimism surrounding Protagonist’s advancements in addressing unmet medical needs.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.